Organon & Co. (NYSE:OGN) Shares Sold by Wells Fargo & Company MN

Wells Fargo & Company MN decreased its position in Organon & Co. (NYSE:OGNFree Report) by 37.4% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 470,463 shares of the company’s stock after selling 280,839 shares during the period. Wells Fargo & Company MN owned about 0.18% of Organon & Co. worth $6,784,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Lindbrook Capital LLC lifted its position in shares of Organon & Co. by 348.3% in the fourth quarter. Lindbrook Capital LLC now owns 1,838 shares of the company’s stock valued at $27,000 after acquiring an additional 1,428 shares in the last quarter. Gladius Capital Management LP lifted its position in shares of Organon & Co. by 65.1% in the fourth quarter. Gladius Capital Management LP now owns 2,176 shares of the company’s stock valued at $31,000 after acquiring an additional 858 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of Organon & Co. in the third quarter valued at $35,000. GAMMA Investing LLC purchased a new stake in shares of Organon & Co. in the fourth quarter valued at $38,000. Finally, Clear Street Markets LLC lifted its position in shares of Organon & Co. by 588.9% in the third quarter. Clear Street Markets LLC now owns 2,294 shares of the company’s stock valued at $40,000 after acquiring an additional 1,961 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on OGN. Piper Sandler upped their price objective on Organon & Co. from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Monday, April 29th. The Goldman Sachs Group upped their price objective on Organon & Co. from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd.

Check Out Our Latest Analysis on Organon & Co.

Organon & Co. Stock Performance

NYSE OGN opened at $20.67 on Friday. The business’s 50-day moving average price is $19.65 and its 200 day moving average price is $17.00. Organon & Co. has a twelve month low of $10.84 and a twelve month high of $24.08. The company has a market capitalization of $5.32 billion, a PE ratio of 5.05, a price-to-earnings-growth ratio of 0.91 and a beta of 0.87. The company has a current ratio of 1.65, a quick ratio of 1.15 and a debt-to-equity ratio of 181.35.

Organon & Co. (NYSE:OGNGet Free Report) last released its earnings results on Thursday, May 2nd. The company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.31. Organon & Co. had a negative return on equity of 360.57% and a net margin of 16.50%. The firm had revenue of $1.62 billion for the quarter, compared to the consensus estimate of $1.57 billion. On average, research analysts predict that Organon & Co. will post 4.3 earnings per share for the current year.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 13th. Stockholders of record on Monday, May 13th will be issued a $0.28 dividend. The ex-dividend date is Friday, May 10th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 5.42%. Organon & Co.’s dividend payout ratio (DPR) is 27.38%.

Organon & Co. Company Profile

(Free Report)

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.

Read More

Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGNFree Report).

Institutional Ownership by Quarter for Organon & Co. (NYSE:OGN)

Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.